Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Stage of Development | 9 | 1 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Therapy Area | 10 | 1 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Indication | 11 | 2 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Companies | 16 | 2 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Products under Development by Universities/Institutes | 18 | 2 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Therapeutics Assessment | 20 | 6 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Companies Involved in Therapeutics Development | 26 | 8 |
| Biogen, Inc. | 26 | 1 |
| BioMAS Ltd. | 27 | 1 |
| MedImmune, LLC | 28 | 1 |
| Merck &Co., Inc. | 29 | 1 |
| SciFluor Life Sciences, LLC | 30 | 1 |
| Tissue Therapies Limited | 31 | 1 |
| TWi Pharmaceuticals, Inc. | 32 | 1 |
| Vascular Pharmaceuticals, Inc. | 33 | 1 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Drug Profiles | 34 | 23 |
| 264-RAD Drug Profile | 34 | 1 |
| AC-301 Drug Profile | 35 | 1 |
| Antibodies to Inhibit AlphaVBeta6 for Oncology Drug Profile | 36 | 1 |
| AS-101 Drug Profile | 37 | 2 |
| BG-00011 Drug Profile | 39 | 1 |
| C-16Y Drug Profile | 40 | 1 |
| cilengitide Drug Profile | 41 | 2 |
| MK-0429 Drug Profile | 43 | 1 |
| OCU-200 Drug Profile | 44 | 1 |
| Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma Drug Profile | 45 | 1 |
| Proagio Drug Profile | 46 | 1 |
| RSF-201 Drug Profile | 47 | 1 |
| SF-0166 Drug Profile | 48 | 1 |
| Small Molecule to Antagonize AlphaVBetaI for Fibrosis Drug Profile | 49 | 1 |
| Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis Drug Profile | 50 | 1 |
| tetraiodothyroacetic acid Drug Profile | 51 | 1 |
| VF-001 Drug Profile | 52 | 1 |
| VF-002 Drug Profile | 53 | 1 |
| VF-003 Drug Profile | 54 | 1 |
| VF-004 Drug Profile | 55 | 1 |
| VPI-2690B Drug Profile | 56 | 1 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Dormant Projects | 57 | 5 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Discontinued Products | 62 | 2 |
| Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Featured News &Press Releases | 64 | 10 |
| May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find | 64 | 1 |
| May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology | 65 | 1 |
| Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av 3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease | 65 | 1 |
| Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 | 66 | 1 |
| Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update | 66 | 1 |
| Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma | 67 | 2 |
| Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide s Pivotal Phase III Trial CENTRIC | 69 | 1 |
| Aug 31, 2010: Stromedix Receives FDA Orphan Drug Designation For STX-100 For Treatment Of Idiopathic Pulmonary Fibrosis | 69 | 1 |
| Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients | 70 | 1 |
| May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma | 71 | 1 |
| Mar 16, 2009: Merck Serono Expands Cilengitide Development Program | 71 | 1 |
| Jan 22, 2009: Stromedix Secures Broad Patent Coverage For Lead Program, Including Compositions Related To Its Lead Product, STX-100 | 72 | 1 |
| Aug 12, 2008: Stromedix Receives Orphan Drug Designation For STX-100 In Chronic Allograft Nephropathy | 72 | 1 |
| Jan 01, 2004: | 73 | 1 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |